GSK Gears Up for Q4 Earnings: Will It Surpass Estimates?
https://www.zacks.com/stock/news/2217328/gsk-gears-up-for-q4-earnings-will-it-surpass-estimates?cid=CS-ZC-FT-analyst_blog|earnings_preview-2217328
Jan 29, 2024 - We expect GSK's specialty products like Arexvy, Cabenuva, Dovato, Bexsero, Trelegy Ellipta and Shingrix to drive fourth-quarter sales performance.
0
Analysts Estimate Bristol Myers Squibb (BMY) to Report a Decline in Earnings: What to Look Out for
https://www.zacks.com/stock/news/2216537/analysts-estimate-bristol-myers-squibb-bmy-to-report-a-decline-in-earnings-what-to-look-out-for?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_9-2216537
Jan 26, 2024 - Bristol Myers (BMY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
0
Novartis (NVS) to Report Q4 Earnings: Is a Beat in Store?
https://www.zacks.com/stock/news/2215142/novartis-nvs-to-report-q4-earnings-is-a-beat-in-store?cid=CS-ZC-FT-analyst_blog|earnings_preview-2215142
Jan 24, 2024 - Novartis' (NVS) key drugs, Entresto, Kisqali and Pluvicto, are likely to have fueled its top and bottom-line numbers in the fourth quarter.
0
GSK (GSK) Reports Next Week: Wall Street Expects Earnings Growth
https://www.zacks.com/stock/news/2215035/gsk-gsk-reports-next-week-wall-street-expects-earnings-growth?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_9-2215035
Jan 24, 2024 - Glaxo (GSK) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
0
Watch GSK amid evidence hearing on Zantac litigation
https://seekingalpha.com/news/4057520-watch-gsk-amid-hearing-on-zantac-litigation?source=feed_sector_healthcare
Jan 23, 2024 - Investors should watch GSK amid a pre-trial hearing over litigation related to the heartburn medication Zantac, which could result in billions of...
0
Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick
https://www.zacks.com/stock/news/2214220/are-you-a-momentum-investor-this-1-stock-could-be-the-perfect-pick?cid=CS-ZC-FT-tale_of_the_tape|zacks_education_momentum_score-2214220
Jan 23, 2024 - Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
0
GSK (GSK) Stock Dips While Market Gains: Key Facts
https://www.zacks.com/stock/news/2213817/gsk-gsk-stock-dips-while-market-gains-key-facts?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_6v2-2213817
Jan 22, 2024 - GSK (GSK) closed at $39.53 in the latest trading session, marking a -0.38% move from the prior day.
0
GSK (GSK) Declines More Than Market: Some Information for Investors
https://www.zacks.com/stock/news/2211130/gsk-gsk-declines-more-than-market-some-information-for-investors?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_6v3-2211130
Jan 16, 2024 - GSK (GSK) closed at $39.88 in the latest trading session, marking a -0.55% move from the prior day.
0
GSK to sell 3.2% stake in spinoff Haleon: report
https://seekingalpha.com/news/4055337-gsk-to-sell-stake-in-spinoff-haleon-report?source=feed_sector_healthcare
Jan 16, 2024 - GSK (GSK) reportedly plans to sell a 3.2% stake in consumer healthcare products company Haleon (HLN), which it spun off in 2019. Read more here.
0
Biotech and pharma companies are betting on a promising class of cancer drugs to drive growth
https://www.cnbc.com/2024/01/14/cancer-drugs-renewed-interest-in-adcs-will-continue-in-2024.html
Jan 14, 2024 - The JPMorgan Healthcare Conference was likely just the beginning of another year of heightened interest and investments in ADC cancer drugs.
0